

1 AMY W. SCHULMAN  
2 DLA PIPER LLP  
3 1251 Avenue of the Americas  
4 New York, NY 10020  
5 Telephone: (212) 335-4500  
6 Facsimile: (212) 335-4501  
7 amy.schulman@dlapiper.com

5 STUART M. GORDON (SBN: 037477)  
6 GORDON & REES LLP  
7 Embarcadero Center West  
8 275 Battery Street, Suite 2000  
9 San Francisco, CA 94111  
Telephone: (415) 986-5900  
Facsimile: (415) 986-8054  
sgordon@gordonrees.com

10 MICHAEL C. ZELLERS (SBN: 146904)  
11 TUCKER ELLIS & WEST LLP  
12 515 South Flower Street, Suite 4200  
13 Los Angeles, CA 90071-2223  
14 Telephone: (213) 430-3400  
15 Facsimile: (213) 430-3409  
16 [michael.zellers@tuckerellis.com](mailto:michael.zellers@tuckerellis.com)

14 Attorneys for Defendant  
PFIZER INC.

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA  
SAN FRANCISCO DIVISION

18 IN RE BEXTRA AND CELEBREX  
19 MARKETING, SALES PRACTICES AND  
20 PRODUCTS LIABILITY LITIGATION ) MDL Docket No. 1699  
21 *This document relates to* ) CASE NO. 3:08-cv-00706-CRB  
22 THEODORE CARTER, )  
23 Plaintiff, ) PFIZER INC.'S ANSWER TO  
24 vs. ) COMPLAINT  
25 PFIZER INC., ) JURY DEMAND ENDORSED  
26 Defendant. ) HEREIN

1 NOW COMES Defendant Pfizer Inc. ("Defendant"), and files this Answer to Plaintiff's  
2 Complaint ("Complaint"), and would respectfully show the Court as follows:

3 **I.**

4 **PRELIMINARY STATEMENT**

5 The Complaint does not state in sufficient detail when Plaintiff was prescribed or used  
6 Celebrex® (celecoxib) ("Celebrex®"). Accordingly, this Answer can only be drafted generally.  
7 Defendant may seek leave to amend this Answer when discovery reveals the specific time  
8 periods in which Plaintiff was prescribed and used Celebrex®.

9 **II.**

10 **ANSWER**

11 **Response to Allegations Regarding Parties, Jurisdiction, and Venue**

12 1. Defendant is without knowledge or information sufficient to form a belief as to the truth  
13 of the allegations in this paragraph of the Complaint regarding Plaintiff's citizenship and  
14 whether Plaintiff used Celebrex®, and, therefore, denies the same. Defendant denies the  
15 remaining allegations in this paragraph of the Complaint.

16 2. Defendant states that this paragraph of the Complaint contains legal contentions to  
17 which no response is required. To the extent that a response is deemed required, Defendant  
18 admits that it is a Delaware corporation with its principal place of business in New York.  
19 Defendant admits that it is registered to do and does business in the State of Maryland.  
20 Defendant denies any wrongful conduct, denies having committed a tort in the State of  
21 Maryland, and denies the remaining allegations in this paragraph of the Complaint.

22 3. Plaintiff's Complaint omits paragraph number 3.

23 4. Defendant states that this paragraph of the Complaint contains legal contentions to  
24 which no response is required. To the extent that a response is deemed required, Defendant is  
25 without knowledge or information sufficient to form a belief as to the truth of the allegations in  
26 this paragraph of the Complaint concerning Plaintiff's citizenship and the amount in  
27 controversy, and, therefore, denies the same. However, Defendant admits that Plaintiff claims  
28 that the parties are diverse and that the amount in controversy exceeds \$75,000, exclusive of

Gordon & Rees, LLP  
275 Battery Street, Suite 2000  
San Francisco, CA 94111

1 interests and costs. Defendant denies the remaining allegations in this paragraph of the  
2 Complaint.

3 5. Defendant states that this paragraph of the Complaint contains legal contentions to  
4 which no response is required. To the extent that a response is deemed required, Defendant is  
5 without knowledge or information sufficient to form a belief as to the truth of the allegations in  
6 this paragraph of the Complaint regarding whether Plaintiff used Celebrex®, and, therefore,  
7 denies the same. Defendant admits that, during certain periods of time, it marketed and co-  
8 promoted Celebrex® in the United States to be prescribed by healthcare providers who are by  
9 law authorized to prescribe drugs in accordance with their approval by the FDA. Defendant  
10 admits that it provided FDA-approved prescribing information regarding Celebrex®.  
11 Defendant admits that it does business in the State of Maryland. Defendant denies any  
12 wrongful conduct and denies the remaining allegations in this paragraph of the Complaint.

13 **Response to Factual Allegations**

14 6. Defendant admits that, during certain periods of time, it marketed and co-promoted  
15 Celebrex® in the United States, including Maryland, to be prescribed by healthcare providers  
16 who are by law authorized to prescribe drugs in accordance with their approval by the FDA.  
17 Defendant admits that it provided FDA-approved prescribing information regarding Celebrex®.  
18 Defendant denies the remaining allegations in this paragraph of the Complaint.

19 7. Defendant is without knowledge or information sufficient to form a belief as to the truth  
20 of the allegations in this paragraph of the Complaint regarding whether Plaintiff used  
21 Celebrex®, and, therefore, denies the same. Defendant states that Celebrex® was and is safe  
22 and effective when used in accordance with its FDA-approved prescribing information.  
23 Defendant denies that Celebrex® caused Plaintiff injury or damage and denies the remaining  
24 allegations in this paragraph of the Complaint.

25 8. Defendant states that Celebrex® was and is safe and effective when used in accordance  
26 with its FDA-approved prescribing information. Defendant states that the potential effects of  
27 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
28 which was at all times adequate and comported with applicable standards of care and law.

1 Defendant denies any wrongful conduct and denies the remaining allegations in this paragraph  
2 of the Complaint.

3 9. Defendant admits that, during certain periods of time, it marketed and co-promoted  
4 Celebrex® in the United States to be prescribed by healthcare providers who are by law  
5 authorized to prescribe drugs in accordance with their approval by the FDA. Defendant admits  
6 that it provided FDA-approved prescribing information regarding Celebrex®. Defendant  
7 denies the remaining allegations in this paragraph of the Complaint.

8 10. Defendant admits that Celebrex® is in a class of drugs that is, at times, referred to as  
9 non-steroidal anti-inflammatory drugs (“NSAIDS”). Defendant states that Celebrex® is a  
10 prescription medication which is approved by the FDA for the following indications: (1) for  
11 relief of the signs and symptoms of osteoarthritis; (2) for relief of the signs and symptoms of  
12 rheumatoid arthritis in adults; (3) for the management of acute pain in adults; (4) for the  
13 treatment of primary dysmenorrhea; (5) to reduce the number of adenomatous colorectal polyps  
14 in familial adenomatous polyposis (FAP) as an adjunct to usual care (e.g., endoscopic  
15 surveillance surgery); (6) for relief of signs and symptoms of ankylosing spondylitis; and (7) for  
16 relief of the signs and symptoms of juvenile rheumatoid arthritis in patients two years of age  
17 and older. Defendant denies the remaining allegations in this paragraph of the Complaint.

18 11. Defendant states that Celebrex® was and is safe and effective when used in accordance  
19 with its FDA-approved prescribing information. Defendant denies any wrongful conduct and  
20 denies the remaining allegations in this paragraph of the Complaint.

21 12. Defendant states that Celebrex® was and is safe and effective when used in accordance  
22 with its FDA-approved prescribing information. Defendant states that the potential effects of  
23 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
24 which was at all times adequate and comported with applicable standards of care and law.  
25 Defendant denies any wrongful conduct and denies the remaining allegations in this paragraph  
26 of the Complaint.

27 13. Defendant states that Celebrex® was and is safe and effective when used in accordance  
28 with its FDA-approved prescribing information. Defendant states that the potential effects of

1 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
2 which was at all times adequate and comported with applicable standards of care and law.  
3 Defendant admits that it provided FDA-approved prescribing information regarding Celebrex®.  
4 Defendant denies the remaining allegations in this paragraph of the Complaint.

5 14. Defendant states that Celebrex® was and is safe and effective when used in accordance  
6 with its FDA-approved prescribing information. Defendant states that the potential effects of  
7 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
8 which was at all times adequate and comported with applicable standards of care and law.  
9 Defendant denies any wrongful conduct and denies the remaining allegations in this paragraph  
10 of the Complaint.

11 15. Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury  
12 or damage, and denies the remaining allegations in this paragraph of the Complaint.

13 **Response to First Cause of Action: Negligence**

14 16. Defendant incorporates by reference its responses to each paragraph of Plaintiff's  
15 Complaint as if fully set forth herein.

16 17. Defendant admits that, during certain periods of time, it marketed and co-promoted  
17 Celebrex® in the United States to be prescribed by healthcare providers who are by law  
18 authorized to prescribe drugs in accordance with their approval by the FDA. Defendant denies  
19 the remaining allegations in this paragraph of the Complaint.

20 18. Defendant states that Celebrex® was and is safe and effective when used in accordance  
21 with its FDA-approved prescribing information. Defendant states that the potential effects of  
22 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
23 which was at all times adequate and comported with applicable standards of care and law.  
24 Defendant denies any wrongful conduct, denies that Celebrex® is unreasonably dangerous, and  
25 denies the remaining allegations in this paragraph of the Complaint.

26 19. Defendant states that this paragraph of the Complaint contains legal contentions to  
27 which no response is required. To the extent that a response is deemed required, Defendant  
28 admits that it had duties as are imposed by law but denies having breached such duties.

Gordon & Rees, LLP  
275 Battery Street, Suite 2000  
San Francisco, CA 94111

1 Defendant states that Celebrex® was and is safe and effective when used in accordance with its  
2 FDA-approved prescribing information. Defendant states that the potential effects of  
3 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
4 which was at all times adequate and comported with applicable standards of care and law.  
5 Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or  
6 damage, and denies the remaining allegations in this paragraph of the Complaint.

7 20. Defendant states that this paragraph of the Complaint contains legal contentions to  
8 which no response is required. To the extent that a response is deemed required, Defendant  
9 admits that it had duties as are imposed by law but denies having breached such duties.  
10 Defendant states that Celebrex® was and is safe and effective when used in accordance with its  
11 FDA-approved prescribing information. Defendant states that the potential effects of  
12 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
13 which was at all times adequate and comported with applicable standards of care and law.  
14 Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or  
15 damage, and denies the remaining allegations in this paragraph of the Complaint.

16 Answering the unnumbered paragraph following Paragraph 20 of the Complaint,  
17 Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or  
18 damage, and denies the remaining allegations in this paragraph of the Complaint.

19 **Response to Second Cause of Action: Strict Products Liability**

20 21. Defendant incorporates by reference its responses to each paragraph of Plaintiff's  
21 Complaint as if fully set forth herein.

22 22. Defendant states that Celebrex® was and is safe and effective when used in accordance  
23 with its FDA-approved prescribing information. Defendant states that the potential effects of  
24 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
25 which was at all times adequate and comported with applicable standards of care and law.  
26 Defendant denies any wrongful conduct, denies that Celebrex® is defective or unreasonably  
27 dangerous, and denies the remaining allegations in this paragraph of the Complaint.

28 23. Defendant states that Celebrex® was and is safe and effective when used in accordance

Gordon & Rees, LLP  
275 Battery Street, Suite 2000  
San Francisco, CA 94111

1 with its FDA-approved prescribing information. Defendant states that the potential effects of  
2 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
3 which was at all times adequate and comported with applicable standards of care and law.  
4 Defendant denies any wrongful conduct, denies that Celebrex® is defective, and denies the  
5 remaining allegations in this paragraph of the Complaint.

6 24. Defendant states that Celebrex® was and is safe and effective when used in accordance  
7 with its FDA-approved prescribing information. Defendant states that the potential effects of  
8 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
9 which was at all times adequate and comported with applicable standards of care and law.  
10 Defendant denies any wrongful conduct, denies that Celebrex® is defective, and denies the  
11 remaining allegations in this paragraph of the Complaint.

12 25. Defendant is without knowledge or information sufficient to form a belief as to the truth  
13 of the allegations in this paragraph of the Complaint regarding whether Plaintiff used  
14 Celebrex®, and, therefore, denies the same. Defendant states that Celebrex® was and is safe  
15 and effective when used in accordance with its FDA-approved prescribing information.  
16 Defendant states that the potential effects of Celebrex® were and are adequately described in its  
17 FDA-approved prescribing information, which was at all times adequate and comported with  
18 applicable standards of care and law. Defendant denies any wrongful conduct, denies that  
19 Celebrex® is defective, and denies the remaining allegations in this paragraph of the  
20 Complaint.

21 26. Defendant states that Celebrex® was and is safe and effective when used in accordance  
22 with its FDA-approved prescribing information. Defendant states that the potential effects of  
23 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
24 which was at all times adequate and comported with applicable standards of care and law.  
25 Defendant denies any wrongful conduct, denies that Celebrex® is defective, and denies the  
26 remaining allegations in this paragraph of the Complaint.

27 27. Defendant states that Celebrex® was and is safe and effective when used in accordance  
28 with its FDA-approved prescribing information. Defendant states that the potential effects of

Gordon & Rees, LLP  
275 Battery Street, Suite 2000  
San Francisco, CA 94111

1 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
2 which was at all times adequate and comported with applicable standards of care and law.  
3 Defendant denies any wrongful conduct, denies that Celebrex® is defective, and denies the  
4 remaining allegations in this paragraph of the Complaint.

5 28. Defendant states that Celebrex® was and is safe and effective when used in accordance  
6 with its FDA-approved prescribing information. Defendant states that the potential effects of  
7 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
8 which was at all times adequate and comported with applicable standards of care and law.  
9 Defendant denies any wrongful conduct, denies that Celebrex® is defective, denies that  
10 Celebrex® caused Plaintiff injury or damage, and denies the remaining allegations in this  
11 paragraph of the Complaint.

12 Answering the unnumbered paragraph following Paragraph 28 of the Complaint,  
13 Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or  
14 damage, and denies the remaining allegations in this paragraph of the Complaint.

15 **Response to Third Cause of Action: Fraud**

16 29. Defendant incorporates by reference its responses to each paragraph of Plaintiff's  
17 Complaint as if fully set forth herein.

18 30. Defendant is without knowledge or information sufficient to form a belief as to the truth  
19 of the allegations in this paragraph of the Complaint regarding whether Plaintiff used  
20 Celebrex®, and, therefore, denies the same. Defendant states that Celebrex® was and is safe  
21 and effective when used in accordance with its FDA-approved prescribing information.  
22 Defendant states that the potential effects of Celebrex® were and are adequately described in its  
23 FDA-approved prescribing information, which was at all times adequate and comported with  
24 applicable standards of care and law. Defendant denies any wrongful conduct, denies that  
25 Celebrex® caused Plaintiff injury or damage, and denies the remaining allegations in this  
26 paragraph of the Complaint.

27 Answering the unnumbered paragraph following Paragraph 30 of the Complaint,  
28 Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or

1 damage, and denies the remaining allegations in this paragraph of the Complaint.

2 **Response to Fourth Cause of Action: Negligent Misrepresentation**

3 31. Defendant incorporates by reference its responses to each paragraph of Plaintiff's  
4 Complaint as if fully set forth herein.

5 32. Defendant admits that, during certain periods of time, it marketed and co-promoted  
6 Celebrex® in the United States to be prescribed by healthcare providers who are by law  
7 authorized to prescribe drugs in accordance with their approval by the FDA. Defendant states  
8 that Celebrex® was and is safe and effective when used in accordance with its FDA-approved  
9 prescribing information. Defendant states that the potential effects of Celebrex® were and are  
10 adequately described in its FDA-approved prescribing information, which was at all times  
11 adequate and comported with applicable standards of care and law. Defendant denies any  
12 wrongful conduct and denies the remaining allegations in this paragraph of the Complaint.

13 33. Defendant incorporates by reference its responses to each paragraph of Plaintiff's  
14 Complaint as if fully set forth herein. Defendant is without knowledge or information sufficient  
15 to form a belief as to the truth of the allegations in this paragraph of the Complaint regarding  
16 whether Plaintiff used Celebrex®, and, therefore, denies the same. Defendant states that  
17 Celebrex® was and is safe and effective when used in accordance with its FDA-approved  
18 prescribing information. Defendant states that the potential effects of Celebrex® were and are  
19 adequately described in its FDA-approved prescribing information, which was at all times  
20 adequate and comported with applicable standards of care and law. Defendant denies any  
21 wrongful conduct, denies that Celebrex® is defective, denies that Celebrex® caused Plaintiff  
22 injury or damage, and denies the remaining allegations in this paragraph of the Complaint,  
23 including all subparts.

24 34. Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury  
25 or damage, and denies the remaining allegations in this paragraph of the Complaint.

26 Answering the unnumbered paragraph following Paragraph 34 of the Complaint,  
27 Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or  
28 damage, and denies the remaining allegations in this paragraph of the Complaint.

Gordon & Rees, LLP  
275 Battery Street, Suite 2000  
San Francisco, CA 94111

## **Response to Fifth Cause of Action: Express Warranty for Goods**

35. Defendant incorporates by reference its responses to each paragraph of Plaintiff's Complaint as if fully set forth herein.

36. Defendant states that this paragraph of the Complaint contains legal contentions to which no response is required. To the extent that a response is deemed required, Defendant admits that it had duties as are imposed by law but denies having breached such duties. Defendant admits that, during certain periods of time, it marketed and co-promoted Celebrex® in the United States to be prescribed by healthcare providers who are by law authorized to prescribe drugs in accordance with their approval by the FDA. Defendant states that Celebrex® was and is safe and effective when used in accordance with its FDA-approved prescribing information. Defendant states that the potential effects of Celebrex® were and are adequately described in its FDA-approved prescribing information, which was at all times adequate and comported with applicable standards of care and law. Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or damage, and denies the remaining allegations in this paragraph of the Complaint.

Answering the unnumbered paragraph following Paragraph 36 of the Complaint, Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or damage, and denies the remaining allegations in this paragraph of the Complaint.

## **Response to Sixth Cause of Action: Implied Warranty**

## **A. Warranty of Merchantability**

37. Defendant incorporates by reference its responses to each paragraph of Plaintiff's Complaint as if fully set forth herein.

38. Defendant is without knowledge or information sufficient to form a belief as to the truth of the allegations in this paragraph of the Complaint regarding whether Plaintiff used Celebrex®, and, therefore, denies the same. Defendant admits that, during certain periods of time, it marketed and co-promoted Celebrex® in the United States to be prescribed by healthcare providers who are by law authorized to prescribe drugs in accordance with their approval by the FDA. Defendant states that Celebrex® was and is safe and effective when used

1 in accordance with its FDA-approved prescribing information. Defendant states that the  
2 potential effects of Celebrex® were and are adequately described in its FDA-approved  
3 prescribing information, which was at all times adequate and comported with applicable  
4 standards of care and law. Defendant denies any wrongful conduct, denies that Celebrex® is  
5 defective, and denies the remaining allegations in this paragraph of the Complaint.

6 39. Defendant states that Celebrex® was and is safe and effective when used in accordance  
7 with its FDA-approved prescribing information. Defendant states that the potential effects of  
8 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
9 which was at all times adequate and comported with applicable standards of care and law.  
10 Defendant denies any wrongful conduct, denies that Celebrex® is defective, denies that  
11 Celebrex® caused Plaintiff injury or damage, and denies the remaining allegations in this  
12 paragraph of the Complaint.

13 **B. Warranty of Fitness**

14 40. Defendant incorporates by reference its responses to each paragraph of Plaintiff's  
15 Complaint as if fully set forth herein.

16 41. Defendant is without knowledge or information sufficient to form a belief as to the truth  
17 of the allegations in this paragraph of the Complaint regarding whether Plaintiff used  
18 Celebrex®, and, therefore, denies the same. Defendant admits that, during certain periods of  
19 time, it marketed and co-promoted Celebrex® in the United States to be prescribed by  
20 healthcare providers who are by law authorized to prescribe drugs in accordance with their  
21 approval by the FDA. Defendant states that Celebrex® was and is safe and effective when used  
22 in accordance with its FDA-approved prescribing information. Defendant states that the  
23 potential effects of Celebrex® were and are adequately described in its FDA-approved  
24 prescribing information, which was at all times adequate and comported with applicable  
25 standards of care and law. Defendant denies any wrongful conduct and denies the remaining  
26 allegations in this paragraph of the Complaint.

27 42. Defendant states that Celebrex® was and is safe and effective when used in accordance  
28 with its FDA-approved prescribing information. Defendant states that the potential effects of

1 Celebrex® were and are adequately described in its FDA-approved prescribing information,  
2 which was at all times adequate and comported with applicable standards of care and law.  
3 Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or  
4 damage, and denies the remaining allegations in this paragraph of the Complaint.

5 Answering the unnumbered paragraph following Paragraph 42 of the Complaint,  
6 Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or  
7 damage, and denies the remaining allegations in this paragraph of the Complaint.

8 **Response to Seventh Cause of Action: Unjust Enrichment**

9 43. Defendant incorporates by reference its responses to each paragraph of Plaintiff's  
10 Complaint as if fully set forth herein.

11 44. Defendant is without knowledge or information sufficient to form a belief as to the truth  
12 of the allegations in this paragraph of the Complaint, and, therefore, denies the same.  
13 Defendant denies the remaining allegations in this paragraph of the Complaint.

14 45. Defendant is without knowledge or information sufficient to form a belief as to the truth  
15 of the allegations in this paragraph of the Complaint regarding whether Plaintiff used  
16 Celebrex®, and, therefore, denies the same. Defendant states that Celebrex® was and is safe  
17 and effective when used in accordance with its FDA-approved prescribing information.  
18 Defendant denies any wrongful conduct and denies the remaining allegations in this paragraph  
19 of the Complaint.

20 46. Defendant is without knowledge or information sufficient to form a belief as to the truth  
21 of the allegations in this paragraph of the Complaint regarding whether Plaintiff used  
22 Celebrex®, and, therefore, denies the same. Defendant states that Celebrex® was and is safe  
23 and effective when used in accordance with its FDA-approved prescribing information.  
24 Defendant denies any wrongful conduct and denies the remaining allegations in this paragraph  
25 of the Complaint.

26 Answering the unnumbered paragraph following Paragraph 46 of the Complaint,  
27 Defendant denies any wrongful conduct, denies that Celebrex® caused Plaintiff injury or  
28 damage, and denies the remaining allegations in this paragraph of the Complaint.

Gordon & Rees, LLP  
275 Battery Street, Suite 2000  
San Francisco, CA 94111

### III.

## **GENERAL DENIAL**

Defendant denies all allegations and/or legal conclusions set forth in Plaintiff's Complaint that have not been previously admitted, denied, or explained.

IV.

## **AFFIRMATIVE DEFENSES**

Defendant reserves the right to rely upon any of the following or additional defenses to claims asserted by Plaintiff to the extent that such defenses are supported by information developed through discovery or evidence at trial. Defendant affirmatively shows that:

## First Defense

1. The Complaint fails to state a claim upon which relief can be granted.

## **Second Defense**

2. Celebrex® is a prescription medical product. The federal government has preempted the field of law applicable to the labeling and warning of prescription medical products. Defendant's labeling and warning of Celebrex® was at all times in compliance with applicable federal law. Plaintiff's causes of action against Defendant, therefore, fail to state a claim upon which relief can be granted; such claims, if allowed, would conflict with applicable federal law and violate the Supremacy Clause of the United States Constitution.

### **Third Defense**

3. At all relevant times, Defendant provided proper warnings, information and instructions for the drug in accordance with generally recognized and prevailing standards in existence at the time.

## **Fourth Defense**

4. At all relevant times, Defendant's warnings and instructions with respect to the use of Celebrex® conformed to the generally recognized, reasonably available, and reliable state of knowledge at the time the drug was manufactured, marketed and distributed.

## **Fifth Defense**

5. Plaintiff's action is time-barred as it is filed outside of the time permitted by the

1 applicable Statute of Limitations, and same is pled in full bar of any liability as to Defendant.

2 **Sixth Defense**

3 6. Plaintiff's action is barred by the statute of repose.

4 **Seventh Defense**

5 7. Plaintiff's claims against Defendant are barred to the extent Plaintiff was contributorily  
6 negligent, actively negligent or otherwise failed to mitigate Plaintiff's damages, and any  
7 recovery by Plaintiff should be diminished accordingly.

8 **Eighth Defense**

9 8. The proximate cause of the loss complained of by Plaintiff is not due to any acts or  
10 omissions on the part of Defendant. Rather, said loss is due to the acts or omissions on the part  
11 of third parties unrelated to Defendant and for whose acts or omissions Defendant is not liable in  
12 any way.

13 **Ninth Defense**

14 9. The acts and/or omissions of unrelated third parties as alleged constituted independent,  
15 intervening causes for which Defendant cannot be liable.

16 **Tenth Defense**

17 10. Any injuries or expenses incurred by Plaintiff were not caused by Celebrex®, but were  
18 proximately caused, in whole or in part, by an idiosyncratic reaction, operation of nature, or act  
19 of God.

20 **Eleventh Defense**

21 11. Defendant affirmatively denies that it violated any duty owed to Plaintiff.

22 **Twelfth Defense**

23 12. A manufacturer has no duty to warn patients or the general public of any risk,  
24 contraindication, or adverse effect associated with the use of a prescription medical product.  
25 Rather, the law requires that all such warnings and appropriate information be given to the  
26 prescribing physician and the medical profession, which act as a "learned intermediary" in  
27 determining the use of the product. Celebrex® is a prescription medical product, available only  
28 on the order of a licensed physician. Celebrex® provided an adequate warning to Plaintiff's

1 treating and prescribing physicians.

2 **Thirteenth Defense**

3 13. The product at issue was not in a defective condition or unreasonably dangerous at the  
4 time it left the control of the manufacturer or seller.

5 **Fourteenth Defense**

6 14. Celebrex® was at all times material to the Complaint reasonably safe and reasonably fit  
7 for its intended use and the warnings and instructions accompanying Celebrex® at the time of  
8 the occurrence of the injuries alleged by Plaintiff was legally adequate for its approved usages.

9 **Fifteenth Defense**

10 15. Plaintiff's causes of action are barred in whole or in part by the lack of a defect as the  
11 Celebrex® allegedly ingested by Plaintiff was prepared in accordance with the applicable  
12 standard of care.

13 **Sixteenth Defense**

14 16. Plaintiff's alleged injuries/damages, if any, were the result of misuse or abnormal use of  
15 the product Celebrex® after the product left the control of Defendant and any liability of  
16 Defendant is therefore barred.

17 **Seventeenth Defense**

18 17. Plaintiff's alleged damages were not caused by any failure to warn on the part of  
19 Defendant.

20 **Eighteenth Defense**

21 18. Plaintiff's alleged injuries/damages, if any, were the result of preexisting or subsequent  
22 conditions unrelated to Celebrex®.

23 **Nineteenth Defense**

24 19. Plaintiff knew or should have known of any risk associated with Celebrex®; therefore,  
25 the doctrine of assumption of the risk bars or diminishes any recovery.

26 **Twentieth Defense**

27 20. Plaintiff is barred from recovering against Defendant because Plaintiff's claims are  
28 preempted in accordance with the Supremacy Clause of the United States Constitution and by the

1 Federal Food, Drug and Cosmetics Act, 21 U.S.C. § 301 et. seq.

2 **Twenty-first Defense**

3 21. Plaintiff's claims are barred in whole or in part under the applicable state law because the  
4 subject pharmaceutical product at issue was subject to and received pre-market approval by the  
5 Food and Drug Administration under 52 Stat. 1040, 21 U.S.C. § 301.

6 **Twenty-second Defense**

7 22. The manufacture, distribution and sale of the pharmaceutical product referred to in  
8 Plaintiff's Complaint were at all times in compliance with all federal regulations and statutes,  
9 and Plaintiff's causes of action are preempted.

10 **Twenty-third Defense**

11 23. Plaintiff's claims are barred in whole or in part by the deference given to the primary  
12 jurisdiction of the Food and Drug Administration over the subject pharmaceutical product at  
13 issue under applicable federal laws, regulations, and rules.

14 **Twenty-fourth Defense**

15 24. Plaintiff's claims are barred in whole or in part because there is no private right of action  
16 concerning matters regulated by the Food and Drug Administration under applicable federal  
17 laws, regulations, and rules.

18 **Twenty-fifth Defense**

19 25. Plaintiff's claims are barred in whole or in part because Defendant provided adequate  
20 "direction or warnings" as to the use of the subject pharmaceutical product within the meaning of  
21 Comment j to § 402A of the Restatement (Second) of Torts.

22 **Twenty-sixth Defense**

23 26. Plaintiff's claims are barred or limited to a product liability failure to warn claim because  
24 Celebrex® is a prescription pharmaceutical drug and falls within the ambit of Restatement  
25 (Second) of Torts § 402A, Comment k.

26 **Twenty-seventh Defense**

27 27. Plaintiff's claims are barred in whole or in part because the subject pharmaceutical  
28 product at issue "provides net benefits for a class of patients" within the meaning of Comment f

Gordon & Rees, LLP  
275 Battery Street, Suite 2000  
San Francisco, CA 94111

1 to § 6 of the Restatement (Third) of Torts: Products Liability.

2 **Twenty-eighth Defense**

3 28. Plaintiff's claims are barred under § 4, et seq., of the Restatement (Third) of Torts:  
 4 Products Liability.

5 **Twenty-ninth Defense**

6 29. To the extent that Plaintiff is seeking punitive damages, Plaintiff has failed to plead facts  
 7 sufficient under the law to justify an award of punitive damages.

8 **Thirtieth Defense**

9 30. Defendant affirmatively avers that the imposition of punitive damages in this case would  
 10 violate Defendant's rights to procedural due process under both the Fourteenth Amendment of  
 11 the United States Constitution and the Constitutions of the States of Maryland and California,  
 12 and would additionally violate Defendant's rights to substantive due process under the  
 13 Fourteenth Amendment of the United States Constitution.

14 **Thirty-first Defense**

15 31. Plaintiff's claims for punitive damages are barred, in whole or in part, by State of  
 16 Maryland law and by the Fifth and Fourteenth Amendments to the United States Constitution.

17 **Thirty-second Defense**

18 32. The imposition of punitive damages in this case would violate the First Amendment to  
 19 the United States Constitution.

20 **Thirty-third Defense**

21 33. Plaintiff's punitive damage claims are preempted by federal law.

22 **Thirty-fourth Defense**

23 34. In the event that reliance was placed upon Defendant's nonconformance to an express  
 24 representation, this action is barred as there was no reliance upon representations, if any, of  
 25 Defendant.

26 **Thirty-fifth Defense**

27 35. Plaintiff failed to provide Defendant with timely notice of any alleged nonconformance to  
 28 any express representation.

## Thirty-sixth Defense

36. To the extent that Plaintiff's claims are based on a theory providing for liability without proof of causation, the claims violate Defendant's rights under the United States Constitution.

## Thirty-seventh Defense

37. Plaintiff's claims are barred, in whole or in part, because the advertisements, if any, and labeling with respect to the subject pharmaceutical products were not false or misleading and, therefore, constitute protected commercial speech under the applicable provisions of the United States Constitution.

## Thirty-eighth Defense

38. To the extent that Plaintiff seeks punitive damages for the conduct which allegedly caused injuries asserted in the Complaint, punitive damages are barred or reduced by applicable law or statute or, in the alternative, are unconstitutional insofar as they violate the due process protections afforded by the United States Constitution, the excessive fines clause of the Eighth Amendment of the United States Constitution, the Commerce Clause of the United States Constitution, the Full Faith and Credit Clause of the United States Constitution, and applicable provisions of the Constitutions of the States of Maryland and California. Any law, statute, or other authority purporting to permit the recovery of punitive damages in this case is unconstitutional, facially and as applied, to the extent that, without limitation, it: (1) lacks constitutionally sufficient standards to guide and restrain the jury's discretion in determining whether to award punitive damages and/or the amount, if any; (2) is void for vagueness in that it failed to provide adequate advance notice as to what conduct will result in punitive damages; (3) permits recovery of punitive damages based on out-of-state conduct, conduct that complied with applicable law, or conduct that was not directed, or did not proximately cause harm, to Plaintiff; (4) permits recovery of punitive damages in an amount that is not both reasonable and proportionate to the amount of harm, if any, to Plaintiff and to the amount of compensatory damages, if any; (5) permits jury consideration of net worth or other financial information relating to Defendant; (6) lacks constitutionally sufficient standards to be applied by the trial court in post-verdict review of any punitive damages awards; (7) lacks constitutionally sufficient

1 standards for appellate review of punitive damages awards; and (8) otherwise fails to satisfy  
2 Supreme Court precedent, including, without limitation, *Pacific Mutual Life Ins. Co. v. Haslip*,  
3 499 U.S. 1 (1991), *TXO Production Corp. v. Alliance Resources, Inc.*, 509 U.S. 443 (1993);  
4 *BMW of North America, Inc. v. Gore*, 519 U.S. 559 (1996); and *State Farm Mut. Auto Ins. Co. v.*  
5 *Campbell*, 538 U.S. 408 (2003).

6 **Thirty-ninth Defense**

7 39. The methods, standards, and techniques utilized with respect to the manufacture, design,  
8 and marketing of Celebrex®, if any, used in this case, included adequate warnings and  
9 instructions with respect to the product's use in the package insert and other literature, and  
10 conformed to the generally recognized, reasonably available, and reliable state of the knowledge  
11 at the time the product was marketed.

12 **Fortieth Defense**

13 40. The claims asserted in the Complaint are barred because Celebrex® was designed, tested,  
14 manufactured, and labeled in accordance with the state-of-the-art industry standards existing at  
15 the time of the sale.

16 **Forty-first Defense**

17 41. If Plaintiff has sustained injuries or losses as alleged in the Complaint, upon information  
18 and belief, such injuries and losses were caused by the actions of persons not having real or  
19 apparent authority to take said actions on behalf of Defendant and over whom Defendant had no  
20 control and for whom Defendant may not be held accountable.

21 **Forty-second Defense**

22 42. The claims asserted in the Complaint are barred, in whole or in part, because Celebrex®  
23 was not unreasonably dangerous or defective, was suitable for the purpose for which it was  
24 intended, and was distributed with adequate and sufficient warnings.

25 **Forty-third Defense**

26 43. Plaintiff's claims are barred, in whole or in part, by the equitable doctrines of laches,  
27 waiver, and/or estoppel.

Gordon & Rees, LLP  
275 Battery Street, Suite 2000  
San Francisco, CA 94111

**Gordon & Rees, LLP**  
**275 Battery Street, Suite 2000**  
**San Francisco CA 94111**

## Forty-fourth Defense

2 44. Plaintiff's claims are barred because Plaintiff's injuries, if any, were the result of the pre-  
3 existing and/or unrelated medical, genetic and/or environmental conditions, diseases or illnesses,  
4 subsequent medical conditions, or natural courses of conditions of Plaintiff, and were  
5 independent of or far removed from Defendant's conduct.

## **Forty-fifth Defense**

7 45. The claims asserted in the Complaint are barred, in whole or in part, because Celebrex®  
8 did not proximately cause injuries or damages to Plaintiff.

## **Forty-sixth Defense**

10 46. The claims asserted in the Complaint are barred, in whole or in part, because Plaintiff did  
11 not incur any ascertainable loss as a result of Defendant's conduct.

## Forty-seventh Defense

13 47. The claims asserted in the Complaint are barred, in whole or in part, because the  
14 manufacturing, labeling, packaging, and any advertising of the product complied with the  
15 applicable codes, standards, and regulations established, adopted, promulgated or approved by  
16 any applicable regulatory body, including but not limited to the United States, any state, and any  
17 agency thereof.

## **Forty-eighth Defense**

19 48. The claims must be dismissed because Plaintiff would have taken Celebrex® even if the  
20 product labeling contained the information that Plaintiff contends should have been provided.

## Forty-ninth Defense

22 49. The claims asserted in the Complaint are barred because the utility of Celebrex®  
23 outweighed its risks.

## Fiftieth Defense

25 | 50. Plaintiff's damages, if any, are barred or limited by the payments received from collateral  
26 | sources.

## Fifty-first Defense

28 || 51. Defendant's liability, if any, can only be determined after the percentages of

1 responsibility of all persons who caused or contributed toward Plaintiff's alleged damages, if  
 2 any, are determined. Defendant seeks an adjudication of the percentage of fault of Plaintiff and  
 3 each and every other person whose fault could have contributed to the alleged injuries and  
 4 damages, if any, of Plaintiff.

5 **Fifty-second Defense**

6 52. Plaintiff's claims are barred, in whole or in part, by the doctrine of abstention in that the  
 7 common law gives deference to discretionary actions by the United States Food and Drug  
 8 Administration under the Federal Food, Drug, and Cosmetic Act.

9 **Fifty-third Defense**

10 53. The claims asserted in the Complaint are barred, in whole or in part, because Celebrex®  
 11 is comprehensively regulated by the FDA pursuant to the Federal Food, Drug & Cosmetic Act  
 12 ("FDCA"), 21 U.S.C. §§ 301 et seq., and regulations promulgated thereunder, and Plaintiff's  
 13 claims conflict with the FDCA, with the regulations promulgated by FDA to implement the  
 14 FDCA, with the purposes and objectives of the FDCA and FDA's implementing regulations, and  
 15 with the specific determinations by FDA specifying the language that should be used in the  
 16 labeling accompanying Celebrex®. Accordingly, Plaintiff's claims are preempted by the  
 17 Supremacy Clause of the United States Constitution, Art. VI, cl. 2, and the laws of the United  
 18 States.

19 **Fifty-fourth Defense**

20 54. Plaintiff's misrepresentation allegations are not stated with the degree of particularity  
 21 required by Federal Rule of Civil Procedure 9(b) and should be dismissed.

22 **Fifty-fifth Defense**

23 55. Defendant states on information and belief that the Complaint and each purported cause  
 24 of action contained therein is barred by the statutes of limitations contained in California Code  
 25 of Civil Procedure §§ 335.1 and 338 and former § 340(3), such other statutes of limitation as  
 26 may apply.

27 **Fifty-sixth Defense**

28 56. Defendant states on information and belief that any injuries, losses, or damages suffered

Gordon & Rees, LLP  
 275 Battery Street, Suite 2000  
 San Francisco, CA 94111

1 by Plaintiff was proximately caused, in whole or in part, by the negligence or other actionable  
 2 conduct of persons or entities other than Defendant. Therefore, Plaintiff's recovery against  
 3 Defendant, if any, should be reduced pursuant to California Civil Code § 1431.2.

4 **Fifty-seventh Defense**

5 57. To the extent that Plaintiff seeks punitive damages for an alleged act or omission of  
 6 Defendant, no act or omission was oppressive, fraudulent, or malicious under California Civil  
 7 Code § 3294, and, therefore, any award of punitive damages is barred. Any claim for punitive  
 8 damages is also barred under California Civil Code § 3294(b).

9 **Fifty-eighth Defense**

10 58. Defendant reserves the right to supplement its assertion of defenses as it continues with  
 11 its factual investigation of Plaintiff's claims.

12 **V.**

13 **JURY DEMAND**

14 Defendant hereby demands a trial by jury of all the facts and issue in this case pursuant to  
 15 Federal Rule of Civil Procedure 38(b).

16 **VI.**

17 **PRAYER**

18 WHEREFORE, Defendant prays for judgment as follows:

- 19 1. That Plaintiff takes nothing from Defendant by reason of the Complaint;
- 20 2. That the Complaint be dismissed;
- 21 3. That Defendant be awarded its costs for this lawsuit;
- 22 4. That the trier of fact determine what percentage of the combined fault or other liability of  
   all persons whose fault or other liability proximately caused Plaintiff's alleged injuries,  
   losses or damages is attributable to each person;
- 23 5. That any judgment for damages against Defendant in favor of Plaintiff be no greater than  
   an amount which equals Plaintiff's proportionate share, if any, of the total fault or other  
   liability which proximately caused Plaintiff's injuries and damages; and
- 24 6. That Defendant has such other and further relief as the Court deems appropriate.

Gordon & Rees, LLP  
 275 Battery Street, Suite 2000  
 San Francisco, CA 94111

March 7, 2008

GORDON & REES LLP

Stuart M. Gordon  
sgordon@gordonrees.com  
Embarcadero Center West  
275 Battery Street, 20<sup>th</sup> Floor  
San Francisco, CA 94111  
Telephone: (415) 986-5900  
Fax: (415) 986-8054

March 7, 2008

TUCKER ELLIS & WEST LLP

Michael C. Zellers  
michael.zellers@tuckerellis.com  
515 South Flower Street, Suite 4200  
Los Angeles, CA 90071-2223  
Telephone: (213) 430-3400  
Fax: (213) 430-3409

Attorneys for Defendant  
PFIZER INC.

**Gordon & Rees, LLP**  
**275 Battery Street, Suite 2000**  
**San Francisco, CA 94111**

1 **JURY DEMAND**

2 Defendant Pfizer Inc. hereby demands a trial by jury of all the facts and issues in this  
3 case pursuant to 38(b) of the Federal Rules of Civil Procedure.

4 March 7, 2008

GORDON & REES LLP

6 By: \_\_\_\_\_/s/

7 Stuart M. Gordon  
8 sgordon@gordonrees.com  
9 Embarcadero Center West  
10 275 Battery Street, 20<sup>th</sup> Floor  
11 San Francisco, CA 94111  
12 Telephone: (415) 986-5900  
13 Fax: (415) 986-8054

14 March 7, 2008

TUCKER ELLIS & WEST LLP

15 By: \_\_\_\_\_/s/

16 Michael C. Zellers  
17 michael.zellers@tuckerellis.com  
18 515 South Flower Street, Suite 4200  
19 Los Angeles, CA 90071-2223  
20 Telephone: (213) 430-3400  
21 Fax: (213) 430-3409

22 Attorneys for Defendant  
23 PFIZER INC.

24 **Gordon & Rees, LLP**  
25 **275 Battery Street, Suite 2000**  
26 **San Francisco, CA 94111**